1 Min Read
May 9 (Reuters) - Sellas Life Sciences Group Inc:
* SELLAS LIFE SCIENCES RECEIVES FDA ORPHAN DRUG DESIGNATION FOR GALINPEPIMUT-S (GPS) FOR TREATMENT OF MULTIPLE MYELOMA (MM) Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.